Nina Lelic

Medicine · Health Sciences

11h-index2.3kcitations68works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(45), Cancer, Hypoxia, and Metabolism(39), ATP Synthase and ATPases Research(10), Histone Deacetylase Inhibitors Research(9), Cancer Research and Treatments(8)

Publications67 total

Data from Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i>-Mutant Gliomas
2023Open Access
Supplementary Figure 5 from Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i>-Mutant Gliomas
2023Open Access
Supplementary Figures from Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
2023Open Access
Supplementary Figure 7 from Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i>-Mutant Gliomas
2023Open Access
Supplementary Figures 1-6 from The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD<sup>+</sup> Depletion–Mediated Cytotoxicity
2023Open Access
Supplementary Figure Legends from The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD<sup>+</sup> Depletion–Mediated Cytotoxicity
2023Open Access
Supplementary Figure 5 from Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i>-Mutant Gliomas
2023Open Access
Supplementary Table 2 from Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i>-Mutant Gliomas
2023Open Access
Data from Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i>-Mutant Gliomas
2023Open Access
Supplementary Table S1 from Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
2023Open Access
Supplementary Table 2 from Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i>-Mutant Gliomas
2023Open Access
Supplementary Figures from Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
2023Open Access
Supplementary Figure 3 from Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i>-Mutant Gliomas
2023Open Access
Supplementary Figure Legends from The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD<sup>+</sup> Depletion–Mediated Cytotoxicity
2023Open Access
Data from PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors
2023Open Access
Data from Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
2023Open Access
Supplementary Table S3 from Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
2023Open Access
Suppl. Fig. Legends and Suppl. Methods from Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
2023Open Access
Supplementary Table from PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors
2023Open Access
Supplementary Table 1 from Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i>-Mutant Gliomas
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Daniel P. Cahill(50), Hiroaki Wakimoto(46), Tracy T. Batchelor(46), Kensuke Tateishi(44), William T. Curry(39), Dora Dias‐Santagata(23), A. John Iafrate(22), Franziska Loebel(20), James C. Kim(20), A. John Iafrate(20), Lindsay K. Klofas(19), Juxiang Chen(18), Leif W. Ellisen(18), Darrell R. Borger(18), Sarah‐Maria Fendt(18), Matthew G. Vander Heiden(18), Mara V.A. Koerner(17), Dan Zhao(16), S. Andrew(16), Julie J. Miller(13)